CLONIT SRL of Siziano at MEDICA 2022 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

For you at the stand

Company news



14 Oct 2022

Clonit announces the acquisition of Experteam

The acquisition represents a further step in the creation of a leading group, supporting our customers in the rapidly growing Molecular Diagnostics Market

More Less

23 Aug 2022

quanty Monkeypox

Multiplex Real-Time PCR kit for the detection and quantification of the 2022 Monkeypox virus DNA.
The assay, designed on the J2L, J2R and D14L regions, can discriminate the two MPXV clades (West Africa and Congo basin), assisting in the Monkeypox virus infection surveillance.

More Less

20 Jun 2022

New Oncohematology products

Clonit, Innovation and Passion to serve Acute myeloid leukemia (AML) diagnosis and monitoring.

We are pleased to announce the recent introduction of the new Oncohematology line of products in our catalogue.
In the last months our R&D department has been deeply engaged in studying and developing three new specific molecular assays that can help the diagnosis of Leukemia. 
The three kits PML-RARA t(15;17)(q22;q21), AML1-ETO t(8;21)(q22;q22) and Inv(16)(p13q22) - CBFB-MYH11, belonging to the new Clonit's Oncohematology line, have been designed following the "Europe Against Cancer (EAC) Guidelines - Leukemia 2003" and they are CE IVD marked according to the IVDD 98/79 CE.
The new molecular assays are based on a one-step Real-Time RT-PCR protocol starting from peripheral blood or bone marrow samples and can be performed on the most common Real-Time PCR Systems.
qRT- PCR shows significant sensitivity in the detection of the translocations or chromosomal abnormalities in patients with Acute myeloid leukemia (AML). Toghether with the cytogenetic analysis it represents an important tool in the screening of acute leukemia patients and should provide useful information for the diagnosis and prognosis even in situations with low patient material and allows patients to be assigned to the appropriate risk group for management and therapy.
Thanks to our passion for health and for a better life, combined with our strong expertise in molecular biology, we are giving our contribution to AML diagnosis and monitoring, helping patients and clinicians fighting AML.

This makes us proud and happy!

Stay tuned on upcoming Clonit innovation news!

More Less

Please log in

You must be logged in to use matchmaking